Sequencing in Breast Cancer
Brian Leyland-Jones, MBBS, PhD, gives an overview of a trial that looks at all aspects of sequencing in breast cancer.
Brian Leyland-Jones, MBBS, PhD, director of Edith Sanford Breast Cancer Research, gives an overview of a trial that looks at all aspects of sequencing in breast cancer.
Clinical Pearls
- A 25-patient trial will analyze all the aspects of sequencing including whole genome sequencing and exome sequencing
- The data from the trial will help guide therapy
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
